For research and educational purposes only. Not medical advice.
Somapacitan Reference
Educational, not medical advice reference for Somapacitan: GH Release, Hormonal; regulatory status, evidence posture, source review, and schedule notes. Also…
Reference summary
Somapacitan is a label-verified long-acting somatropin analog dosed once weekly. pepSmart surfaces label-reference content only.
- Categories
- GH Release, Hormonal
- Aliases
- Sogroya, Long-acting somatropin analog
- Evidence posture
- human — Recombinant human growth hormone analog. WADA-prohibited at all times under category S2. Prescription-only; possession or distribution outside an FDA-approved indication is restricted by the Anabolic Steroid Control Act.
- Regulatory status
- FDA-approved prescription medication (Sogroya). Indicated for adults with growth hormone deficiency. WADA-prohibited under category S2 at all times. Distribution and possession outside an approved indication is restricted under the United States Anabolic Steroid Control Act.
- Content review status
- label verified